Olanzapine in Chinese treatment-resistant patients with schizophrenia: An open-label, prospective trial

Psychiatry and Clinical Neurosciences

Volumn 57, Issue 5, 2003, Pages 478-484

  Chiu, Nan Ying ^a   Yang, Yen Kuang ^b   Chen, Po See ^b   Chang, Cheng Chen ^a   Lee, I Hui ^b   Lee, Jiunn Ren ^a  

^a CHANGHUA CHRISTIAN HOSPITAL   (Taiwan)

^b NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

Author keywords

Olanzapine; Open label trial; Treatment resistant schizophrenia

Indexed keywords

CHLORPROTHIXENE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLOZAPINE; FLUPENTIXOL; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PIPOTIAZINE; RISPERIDONE; SULPIRIDE; TRIFLUOPERAZINE;

ADULT; ARTICLE; CHINA; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; NERVOUSNESS; PATIENT COMPLIANCE; PSYCHOSIS; RATING SCALE; SCHIZOPHRENIA; SIDE EFFECT; SINGLE BLIND PROCEDURE; SYMPTOMATOLOGY; WEIGHT GAIN;

ADULT; ANTIPSYCHOTIC AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; BENZODIAZEPINES; BRIEF PSYCHIATRIC RATING SCALE; FEMALE; HUMANS; MALE; PIRENZEPINE; PROSPECTIVE STUDIES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TAIWAN; TREATMENT OUTCOME;

EID: 0141928114     PISSN: 13231316     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1819.2003.01151.x     Document Type: Article

References (39)

1. Ciompi L. The natural history of schizophrenia in the long term. Br. J. Psychiatry 1980; 136: 413-420.
2. Kane JM. Schizophrenia. N. Engl. J. Med. 1996; 334: 34-41.
3. Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch. Gen. Psychiatry 1988; 45: 789-796.
4. Ishigooka J, Murasaki M, Miura S. Olanzapine optimal dose: Results of an open-label multicenter study in schizophrenic patients. Olanzapine Late-Phase II Study Group. Psychiatry Clin. Neurosci. 2000; 54: 467-478.
5. Conley RR, Tamminga CA, Bartko JJ et al. Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia. Am. J. Psychiatry 1998; 155: 914-920.
6. Shen WW. The metabolism of atypical antipsychotic drugs: An update. Ann. Clin. Psychiatry 1999; 11: 145-158.
7. Tollefson GD, Birkett MA, Kiesler GM, Wood AJ and Lilly Resistant Schizophrenia Study Group. Double-blind comparison of olanzapine versus clozapine in schizophrenic patients clinically eligible for treatment with clozapine. Biol. Psychiatry 2001; 49: 52-63.
8. Bronson BD, Lindenmayer JP. Adverse effects of high-dose olanzapine in treatment-refractory schizophrenia. J. Clin. Psychopharmacol. 2000; 20: 382-384.
9. Mountjoy CQ, Baldacchino AM, Stubbs JH. British experience with high-dose olanzapine for treatment-refractory schizophrenia. Am. J. Psychiatry 1999; 156: 158-159.
10. Sheitman BB, Lindgren JC, Early J, Sved M. High-dose olanzapine for treatment-refractory schizophrenia. Am. J. Psychiatry 1997; 154: 1626.
11. Martin J, Gomez JC, Garcia-Bernardo E, Cuesta M, Alvarez E, Gurpegui M. Olanzapine in treatment-refractory schizophrenia: Results of an open-label study. The Spanish Group for the Study of Olanzapine in Treatment-Refractory Schizophrenia. J. Clin. Psychiatry 1997; 58: 479-483.
12. Chang WH, Jann MW, Hwu HG et al. Ethnic comparison of haloperidol and reduced haloperidol plasma levels: Taiwan Chinese versus American non-Chinese. J. Formos. Med. Assoc. 1991; 90: 572-578.
13. Kane JM, Honigfeld G, Singer J, Meltzer H. Clozapine in treatment-resistant schizophrenics. Psychopharmacol. Bull. 1988; 24: 62-67.
14. Overall JE, Beller SA. The Brief Psychiatric Rating Scale (BPRS) in geropsychiatric research. I. Factor structure on an inpatient unit. J. Gerontol. 1984; 39: 187-193.
15. Guy W. Early Clinical Drug Evaluation Unit Assessment Manual for Psychopharmacology, Revised Edition. Department of Health, Education and Welfare, Washington DC, 1976
16. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 1987; 13: 261-276.
17. Anonymous. Abnormal Involuntary Movement Scale (AIMS). Psychopharmacol. Bull. 1988; 24: 781-783.
18. Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr. Scand. Suppl. 1970; 212: 11-19.
19. Barnes TR. A rating scale for drug-induced akathisia. Br. J. Psychiatry 1989; 154: 672-676.
20. Ishigooka J, Inada T, Miura S. Olanzapine versus haloperidol in the treatment of patients with chronic schizophrenia: Results of the Japan multicenter, double-blind olanzapine trial. Psychiatry Clin. Neurosci. 2001; 55: 403-414.
21. Ishigooka J, Murasaji M, Miura S and The Olanzapine Early-Phase, I. I. Study Group. Efficacy and safety of olanzapine, and atypical antipsychotic, in patients with schizophrenia: Results of an open-label multicenter study in Japan. Psychiatry Clin. Neurosci. 2001; 55: 353-363.
22. Ishigooka J, Murasaki M, Miura S and the Olanzapine Late-Phase, I. I. Study Group. Olanzapine optimal dose: Results of an open-label multicenter study in schizophrenic patients. Psychiatry Clin. Neurosci. 2000; 54: 467-478.
23. Taylor D, Drummond S, Pendlebury J. Olanzapine in practice. Psychiatr. Bull. 1998; 22: 552-554.
24. Kasper S. Risperidone and olanzapine: Optimal dosing for efficacy and tolerability in patients with schizophrenia. Int. Clin. Psychopharmacol. 1998; 13: 253-262.
25. Chiu H, Lee S, Leung CM, Wing YK. Neuroleptic prescription for Chinese schizophrenics in Hong Kong. Aust. N.Z. J. Psychiatry 1992; 26: 262-264.
26. Jann MW, Chang WH, Lam YW et al. Comparison of haloperidol and reduced haloperidol plasma levels in four different ethnic populations. Prog. Neuropsychopharmacol. Biol. Psychiatry 1992; 16: 193-202.
27. Potkin SG, Shen Y, Pardes H et al. Haloperidol concentrations elevated in Chinese patients. Psychiatry Res. 1984; 12: 167-172.
28. Jann MW, Chang WH, Davis CM et al. Haloperidol and reduced haloperidol plasma levels in Chinese vs. non-Chinese psychiatric patients. Psychiatry Res. 1989; 30: 45-52.
29. Volavka J, Czobor P, Sheitman B et al. Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. Am. J. Psychiatry 2002; 159: 255-262.
30. Littrell KH, Johnson CG, Hilligoss NM, Peabody CD, Littrell SH. Switching clozapine responders to olanzapine. J. Clin. Psychiatry 2000; 61: 912-915.
31. Delassus-Guenault N, Jegouzo A, Odou P et al. Clozapine-olanzapine: A potentially dangerous switch. A report of two cases. J. Clin. Pharm. Ther. 1999; 24: 191-195.
32. Kraus T, Haack M, Schuld A et al. Body weight and leptin plasma levels during treatment with antipsychotic drugs. Am. J. Psychiatry 1999; 156: 312-314.
33. Ober SK, Hudak R, Rusterholtz A. Hyperglycemia and olanzapine. Am. J. Psychiatry 1999; 156: 970.
34. Lindenmayer JP, Smith RC, Singh A, Parker B, Chou E, Kotsaftis A. Hyperglycemia in patients with schizophrenia who are treated with olanzapine. J. Clin. Psychopharmacol. 2001; 21: 351-353.
35. Goldstein LE, Sporn J, Brown S et al. New-onset diabetes mellitus and diabetic ketoacidosis associated with olanzapine treatment. Psychosomatics 1999; 40: 438-443.
36. Wirshing DA, Spellberg BJ, Erhart SM, Marder SR, Wirshing WC. Novel antipsychotics and new onset diabetes. Biol. Psychiatry 1998; 44: 778-783.
37. Von Hayek D, Huttl V, Reiss J, Schweiger HD, Fuessl HS. [Hyperglycemia and ketoacidosis associated with olanzapine]. Nervenarzt 1999; 70: 836-837.
38. Seaburg HL, McLendon BM, Doraiswamy PM. Olanzapine-associated severe hyperglycemia, ketonuria, and acidosis: Case report and review of literature. Pharmacotherapy 2001; 21: 1448-1454.
39. Ragucci KR, Wells BJ. Olanzapine-induced diabetic ketoacidosis. Ann. Pharmacother. 2001; 35: 1556-1558.